Matrix Metalloproteinase Inhibitors (MMP) are potential anti-neoplastics with antitumor and anti-angiogenic effects. A broad spectrum inhibitor of MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7, Marimastat administration is associated with a painful joint condition known as Musculoskeletal Syndrome (MSS) which is characterized by changes in the cartilage, synovium and periarticular tissues. At CBI, we are offering an excellent model of MSS in rats induced by continuous infusion of marimastat for 2 or more weeks. New potentially therapeutic MMPs can be comparatively assessed for their ability to induce MMS in comparison to marimastat.
